Free Trial
NASDAQ:COCP

Cocrystal Pharma Q2 2026 Earnings Report

Cocrystal Pharma logo
$1.11 -0.04 (-3.06%)
Closing price 04:00 PM Eastern
Extended Trading
$1.14 +0.02 (+2.25%)
As of 05:47 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Cocrystal Pharma EPS Results

Actual EPS
-$0.23
Consensus EPS
-$0.17
Beat/Miss
Missed by -$0.06
One Year Ago EPS
N/A

Cocrystal Pharma Revenue Results

Actual Revenue
$0.11 million
Expected Revenue
$0.11 million
Beat/Miss
Beat by +$5.00 thousand
YoY Revenue Growth
N/A

Cocrystal Pharma Announcement Details

Quarter
Q2 2026
Time
Before Market Opens
Conference Call Date
N/A
Conference Call Time
N/A

Upcoming Earnings

Cocrystal Pharma's next earnings date is estimated for Friday, November 13, 2026, based on past reporting schedules.

Conference Call Resources

Cocrystal Pharma Earnings Headlines

The end may be near for these iconic stocks
Marc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are triggering a historic wealth transfer already underway in 2026. Household names like Intuit (-57%), Boston Scientific (-49%), and Tractor Supply (-40%) are cratering, while lesser-known companies like Sandisk (+573%) and Rackspace (+444%) surge. Chaikin has identified specific stocks he believes investors should sell before they fall further - and the names may surprise you. He's also pinpointing a company tapped as Nvidia's self-driving partner and a potential AI megadeal that could split into three high-growth stocks. Stream his free presentation to get every buy and sell recommendation with no membership or credit card required.tc pixel
COCP: $5 Million Private Placement with OPKO Health
See More Cocrystal Pharma Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Cocrystal Pharma? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Cocrystal Pharma and other key companies, straight to your email.

About Cocrystal Pharma

Cocrystal Pharma (NASDAQ:COCP) is a clinical-stage biotechnology company focused on developing antiviral therapeutics for serious and potentially life-threatening viral infections. The company uses structure-based drug design and other drug-discovery technologies to develop small-molecule candidates intended to target highly conserved viral replication proteins.

Its development programs have focused on infections including influenza A and B, norovirus and coronaviruses. Cocrystal’s investigational pipeline has included CC-42344, an orally administered influenza A polymerase inhibitor, and programs targeting norovirus and other viral pathogens. These candidates remain under clinical or preclinical development and are not approved for commercial use.

Cocrystal Pharma is based in Bothell, Washington, and has historically operated as a research-oriented biotechnology company serving global infectious-disease markets through its drug-development programs and collaborations. The company’s leadership has included Gary Wilcox as president and chief executive officer. As a clinical-stage company, Cocrystal’s operations are primarily centered on research, clinical development and potential partnering rather than the sale of marketed products.

View Cocrystal Pharma Profile